Literature DB >> 8507076

p53 Protein expression in nevi and melanomas.

M Cristofolini1, S Boi, S Girlando, G Zumiani, P Cristofolini, P Dalla Palma, C Doglioni, M Barbareschi.   

Abstract

p53 Protein immunohistochemical expression is a wide-spread feature of the malignant phenotype; most melanomas are reported as p53 positive, while nevi are reported as p53 negative. We investigate a series of 75 benign nevi and 47 melanomas (40 primary and seven metastatic) to evaluate their pattern of p53 immunoreactivity with a panel of specific antibodies (PAb1801, PAb240, DO7, and CM1) in view of a possible diagnostic role of p53 immunostaining. Our results demonstrate that 15% of nevi show p53 immunoreactive nuclei (usually in less than 1% of the cells) and that 30% of melanomas show p53 immunoreactive nuclei (one case with 20% immunoreactive cells, six cases with 1% to 5% positive cells, and four cases with less than 1% positive nuclei). p53 Positivity was seen also in basal and suprabasal keratinocytes. p53 Positivity in nevi is at variance with literature data supporting that nevi are p53 negative. p53 Positivity in nevi and in epidermis may be related to mechanisms of DNA repair, apoptosis, or to a specific phase of the cell cycle. In our series, p53 expression in melanomas is not as frequent as reported in the literature. Population-based differences or differences in case selection and sample handling may account for the above discrepancies. The demonstration of p53 positivity in benign skin lesions greatly hinders the possibility of a diagnostic use of p53 immunostaining in dermatopathology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507076

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  9 in total

1.  c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.

Authors:  J S Chana; G D Wilson; I A Cree; R A Alexander; N Myatt; M Neale; A J Foss; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

Review 2.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

Review 3.  Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

4.  DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines.

Authors:  K Rass; P Gutwein; C Welter; V Meineke; W Tilgen; J Reichrath
Journal:  Histochem J       Date:  2001-08

5.  Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.

Authors:  L G Kindblom; M Ahldén; J M Meis-Kindblom; G Stenman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Immunohistochemical detection of p53 protein in cutaneous lesions from transplant recipients harbouring human papillomavirus DNA.

Authors:  I Pélisson; Y Chardonnet; S Euvrard; D Schmitt
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

Authors:  T Papp; M Jafari; D Schiffmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Expression of the p53 protein in malignant melanomas as a prognostic indicator.

Authors:  M Yamamoto; H Takahashi; K Saitoh; T Horikoshi; M Takahashi
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

9.  Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones.

Authors:  K L van Golen; S Risin; A Staroselsky; D Berger; M A Tainsky; S Pathak; J E Price
Journal:  Clin Exp Metastasis       Date:  1996-03       Impact factor: 5.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.